About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma and Beyond - the Role of Cytoreductive Nephrectomy and Biomarkers
By
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
FEATURING
Jeffrey Graham
By
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
FEATURING
Jeffrey Graham
377 views
April 24, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
21:09
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Featured Video
19:22
Janssen Oncology
Doc Talk Podcast
Feat.
J. Hamilton,
M. Fabrizio,
M. Taha
Related Content
AUTOPLAY
ON
16:05
Insights from 2024 ASCO® GU Annual Meeting
Recent GU Developments and Their Clinical Implications
Feat.
T. Powles,
B. Rini
13:37
SIR 2023 Conference Coverage
SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?
Feat.
N. Kothary
15:58
Total Health
Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024
Feat.
M. Reimers
07:27
Jason Levy
Opus One: Final Results - RFA in Axial Skeleton
19:41
Balazs Halmos
How I Manage Immune Adverse Events in Solid Tumors
17:50
AdventHealth
Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…
Feat.
G. Sonpavde
07:10
Viktor Grünwald
Updated Results From the CLEAR Trial: Outcomes of the Combination of…
16:19
OncoAlert
Year in Review: RCC Practice Changing and Practice Informing Trials …
Feat.
T. Choueiri
09:12
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Cabozantinib, Nivolumab, and Ipilimumab f…
Feat.
B. McGregor
15:17
ASCO GU 2023 Conference Coverage
ASCO GU 2023 Systemic Therapy for Recurrent Metastatic RCC: Beyond S…
Feat.
T. Zhang
15:44
Matthew Campbell
How to Select Frontline Therapy for Metastatic Clear Cell RCC
09:35
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "State-of-the-Art in Adjuvant Treatment of …
Feat.
G. de Velasco
23:16
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Optimizing Therapy Selection for Patients…
Feat.
B. McGregor
10:27
Robert McBane
2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Pr…
09:54
Insights from 2024 ASCO® GU Annual Meeting
The Impact of Immunotherapy-Based Regimens in Primary Renal Tumors
Feat.
R. McKay
09:03
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Insights: "Long-Term Follow-Up Data From the Chec…
Feat.
D. McDermott
15:50
Pavlos Msaouel
First-Line Treatment Options in Advanced RCC: How to Choose
13:22
OncoAlert
Urology Year in Review: Prostate Cancer Screening, EMBARK Trial, PSM…
Feat.
A. Merseburger
19:42
International Urology Cancer Summit - IUCS
How to Choose 1L Therapy for mRCC
Feat.
M. Pal
52:18
The France Foundation
Immune Checkpoint Inhibitors & RCC: Where Are We Now?
Feat.
P. Barata,
T. Zhang,
K. Virdee
